Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: An experiment with isolated rat hearts

National Medical Journal of China

Volumn 85, Issue 47, 2005, Pages 3350-3353

  Zhang, Ying Jie ^a   Bai, Xiao Juan ^b   Qi, Zhi Min ^b   Wang, Hong Xin ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Bradykinin; Myocardial reperfusion injury; Valsartan

Indexed keywords

BRADYKININ; BUFFER; CREATINE KINASE MB; EVANS BLUE; ICATIBANT; VALSARTAN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG MECHANISM; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; ISOLATED HEART; NONHUMAN; RAT; RAT STRAIN; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE;

ANIMALS; BRADYKININ; CARDIOTONIC AGENTS; CREATINE KINASE, MB FORM; DISEASE MODELS, ANIMAL; MALE; MYOCARDIAL REPERFUSION INJURY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B2; TETRAZOLES; VALINE; VENTRICULAR FUNCTION, LEFT;

EID: 32444432528     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schulz R, Heusch G. AT1-receptor blockade in experimental myocardial ischemia/reperfusion. J Clin Nephrol, 2003, 60:67-74.
2. Maggioni AP, Fabbri G. VALIANT (Valsartan In acute myocardial infarction) trial. Expert Opin Pharmacother, 2005,6:507-512.
3. Zhang YJ, Liu RG. The effect of valsartan on myocardial infarction area in ischemia-reperfusion rats. J Clin Cardiol, 2002, 18: 179-180.
4. Zhang YJ, Liu RG, Wang HX, et al. The preventing effects of valsartan against ischemia and reperfusion arrhythmias in rat hearts. Chin J Cardiol, 2003,31:829.
5. Barsotti A, Di Napoli P, Taccardi AA, et al. MK-954 (losartan potassium) exert endothelial protective effects against reperfusion injury: evidenced of an e-NOS mRNA overexpression after global ischemia. J Atherosclerosis, 2001,155: 53-59.
6. Shimizu M, Wang QD, Sjoquist PO, et al. The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts. J Cardiovasc Pharmacol, 1999, 34: 78-81.
7. Zhu B, Sun Y, Sievers RE, et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol, 2000,35: 787-795.
8. Bai XJ, Li H, Yang Y, et al. The experimental study of losartan protective effect on cardiac and arterial aging. Chin J Gerontology, 2005,25:171-173.
9. Jugutt BI, Menon V. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Mol Cell Biochem, 2004,260:111-118.
10. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation, 2002,105:656-662.
11. Linz W, Wiemer G, Scholkens BA. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardial, 1997,80:118A-23A.
12. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation, 2005,111:315-320.
13. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest, 1999, 104: 925-935.
14. Liu YH, Xu J, Yang XF, et al. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hyperten, 2002,39:375-381.
15. Xu J, Carretero OA, Liu YH, et al. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension, 2002, 40:244-250.
16. Cui ST, Zhu HS. Myocardial ischemic reperfusion injury affected by the isozymes of nitric oxide synthase and their gene expession: experimental study. Natl Med J China, 1998,78: 327-330.